Background: Topical steroids are widely used in dermatology for their anti-inflammatory and immunosuppressive effects, but misuse can cause skin thinning and systemic issues. In Ethiopia, where skin conditions are common, understanding how topical steroids are prescribed and used is essential for ensuring their safe and effective use.
Objective: The study aimed to assess topical steroids' prescription and utilization pattern in Dessie Comprehensive Specialized Hospital (DCSH) from February 1 to May 30, 2024.
Methodology: The study used a descriptive, cross-sectional design with a quantitative approach, analyzing data from 175 patient records on prescription and utilization patterns of topical steroids at DCSH. Participants were selected using a random sampling technique. Data were categorized and analyzed using Microsoft Excel 2010, with findings presented through descriptive statistics, including tables and figures.
Result: Eczematous dermatitis (31.49%) was the most common skin disease observed, followed by dermatophytosis (12.15%). Out of 304 drugs prescribed, averaging 1.73 per prescription, clobetasol (44.4%) and betamethasone (25.0%) were the most common topical corticosteroids. These steroids were primarily prescribed for eczema, dermatitis, pigmentary disorders, psoriasis, urticaria, and lichen planus. The commonly prescribed drugs were topical steroids 108[35.53%]. Generic names were used for 54.63% of the 108 topical steroids prescribed.
Conclusion: The study found that dermatitis and eczema are the most common skin conditions treated in dermatology clinics, with topical steroids being the main treatment. However, many prescriptions lacked details on the application site, treatment duration, and quantity. To improve safety and effectiveness, the study recommends community education, better dermatological services, and increased oversight in professional training.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717826 | PMC |
http://dx.doi.org/10.1007/s00403-024-03733-3 | DOI Listing |
BMC Ophthalmol
January 2025
Department of Ophthalmology, Tokyo Women's Medical University, 8-1 Kawadacho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Background: To report a case of intraocular inflammation (IOI) after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration.
Case Presentation: An 80-year-old man with diabetes mellitus had neovascular age-related macular degeneration refractory to treatment with aflibercept 2 mg. Despite ten injections of faricimab, the exudation remained, and we switched to brolucizumab, which resulted in a mild IOI.
BMJ Case Rep
January 2025
University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry, UK
A woman in her 50s presented with redness, eye pain, watering and photophobia of the left eye starting 1 week after she tested positive for COVID-19. She was diagnosed with left eye episcleritis and started on topical steroids. As the steroids were being gradually tapered, she developed a recurrence.
View Article and Find Full Text PDFTransl Vis Sci Technol
January 2025
Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Purpose: To clarify the clinical and imaging characteristics of Candida keratitis using in vivo confocal microscopy (IVCM) for improved early diagnosis and management.
Methods: A retrospective study of 40 patients with Candida keratitis at Beijing Tongren Hospital from January 2015 to December 2023 was conducted. Data included demographics, risk factors, clinical assessments, lab tests, and IVCM images.
JAMA Ophthalmol
January 2025
Truhlsen Eye Center, Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha.
Importance: Randomized clinical trials have shown the safety and efficacy of faricimab as a novel vascular endothelial growth factor and angiopoietin-2 inhibitor in the treatment of neovascular age-related macular degeneration (nAMD) and macular edema of various etiologies. However, more rare adverse events may not be considered in clinical trials.
Objective: To describe 3 eyes that developed irreversible vision loss following initial mild intraocular inflammation (IOI) to faricimab.
Lasers Med Sci
January 2025
Plastic Surgery Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Hypertrophic scars (HTSs) are the result of an abnormal healing process resulting from burns and other severe traumas. The symptoms of that condition include skin irritation, discomfort, and itching. This study aimed to assess the efficacy of fractional carbon dioxide (CO) laser therapy alone or with triamcinolone or 5-fluorouracil (FU) in the treatment of early post-burn hypertrophic scars (HTSs) that develop during the first 6 months after the injury.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!